A Study Comparing Dosing Regimens and Efficacy of Subcutaneous to Intravenous Azacitidine (AZA) for the Treatment of Myelodysplastic Syndromes (MDS).
Mikkael A. Sekeres(University of Miami), Kristen Sullivan(Tufts University), David L. Grinblatt(NorthShore University HealthSystem), Julie G. Baker, James Malone(Bigfoot Biomedical (United States)), David W. Donley(Statistical Service), Alan F. List(TE Laboratories (Ireland)), Jaroslaw P. Maciejewski(Cleveland Clinic), Rami S. Komrokji(Moffitt Cancer Center), David A. Sweet, Mohit Narang(Gettysburg College)
Cited by 15
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k